HOME >> BIOLOGY >> NEWS
Control of intestinal inflammation by PGE2 and its receptor

Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have as a common side effect the ability to damage the lining of the intestine. Since NSAIDs inhibit prostanoid biosynthesis, it is accepted that the gastric complications reflect a protective role of some prostaglandins in suppressing intestinal inflammation and damage. Still, the identity of the relevant prostaglandins has not been known, and the involvement of multiple prostaglandin receptors in this beneficial response could not be excluded. Now, however, Kabashima et al. provide a surprisingly simple answer. Taking advantage of the many mouse knockout strains available that lack one or another of the prostaglandin receptors, they show that the prostaglandin PGE2, acting through a single receptor, EP4, is largely if not single-handedly responsible for maintaining the integrity of the intestinal mucosa. While EP4-deficient mice do not ordinarily show symptoms of colitis, the authors find that they are hypersensitive to damage by low doses of the proinflammatory compound dextran sodium sulfate-- doses that are well tolerated by wild-type mice and by animals with mutations in the other receptor genes. Conversely, NSAID treatment, coupled with low-dose DSS, can cause acute disease even in wild-type mice, but treatment with a specific EP4 agonist prevents this response. Hence, this class of agonist might be useful in protecting humans from NSAID gastrotoxicity and might also prove beneficial for ulcerative colitis and Crohn disease, conditions where the gastric mucosa is prone to inflammation and tissue damage.


'"/>

Contact: John Ashkenas
scied@the-jci.org
416-946-7593
Journal of Clinical Investigation
27-Mar-2002


Page: 1

Related biology news :

1. Controlling biomolecules with magnetic tweezers
2. Controlling the internal clock in darkness
3. Controlling body size by regulating the number of cells
4. Controlling cell adhesion: Researchers report first evidence of catch bonds
5. Control of fat cell development demonstrated using Sangamo BioSciences ZFP technology
6. Controlled nerve growth factor aids brain cell transplant
7. Controlling greenhouse gas carbon dioxide through carbon sequestration two-day symposium, April 2-3
8. New Gene Holds Promise For Controlling Crohns And Other Inflammatory Diseases
9. Researchers Discover Fast Efficient, Controllable Way To Study Molecular Interactions
10. Discovery Of A Molecule That Controls Bile Acids May Lead To New Cholesterol Drugs
11. Dual Control Strategy Assures Accurate Cellular Marching Orders, But A Pathogenic Microbe Can Hijack The System

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Control intestinal inflammation PGE2 and its receptor

(Date:2/5/2015)... Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... RedChip Global Online CEO Conference on January 29 th ... Gino Pereira , CEO of NXT-ID will present and ... the Wocket smart wallet and its full suite of ...
(Date:2/5/2015)... 3, 2015 Despite a lack of ... such as consumer electronics, automotive, storage and telecommunication ... technology (SMT) screen printers. Innovations in electronics and ... push the adoption curve up. Meanwhile, sale volumes ... glue dispensers are indispensable in the production of ...
(Date:1/22/2015)... FindBiometrics, the leading source of biometrics industry news, interviews and ... "When we launched FindBiometrics 12 years ago the ... founder and CEO of FindBiometrics. "Now it,s maturing very quickly. ... players on a very broad scale.  We are known for ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
(Date:2/27/2015)... , Feb. 27, 2015 Research and Markets ... "Global Market Report of Trypsin" report to their ... (CAS 9002-07-7) aims at providing comprehensive data on Trypsin globally ... , North America , ... pays close attention to Trypsin This report focuses ...
(Date:2/27/2015)... Australia , Feb. 27, 2015 Bionomics ... from the DisrupTOR-1 trial of BNC105 in patients with ... in Orlando, Florida . The data ... of the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and ...
(Date:2/27/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... with patients and health care advocates in the United ... Day®. Rare Disease Day is dedicated to elevating ... the special challenges faced by patients with rare diseases ... proud to stand alongside patients and caregivers representing the ...
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
Breaking Biology Technology:Global Market Report of Trypsin 2014-2018 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5
Cached News: